Share on StockTwits

Equities research analysts at JMP Securities assumed coverage on shares of Pacira Pharmaceuticals (NASDAQ:PCRX) in a research note issued to investors on Tuesday, TheFlyOnTheWall.com reports. The firm set a “market perform” rating on the stock.

In other Pacira Pharmaceuticals news, Director Andreas Wicki sold 67,900 shares of the stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $82.62, for a total transaction of $5,609,898.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link.

Other equities research analysts have also recently issued reports about the stock. Analysts at Goldman Sachs initiated coverage on shares of Pacira Pharmaceuticals in a research note on Monday, June 2nd. They set a “buy” rating and a $93.00 price target on the stock. Separately, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Thursday, May 15th. They now have a $81.00 price target on the stock. Finally, analysts at Jefferies Group reiterated a “buy” rating on shares of Pacira Pharmaceuticals in a research note on Wednesday, May 7th. They now have a $81.00 price target on the stock. Nine equities research analysts have rated the stock with a buy rating, The stock has a consensus rating of “Buy” and an average price target of $77.92.

Shares of Pacira Pharmaceuticals (NASDAQ:PCRX) opened at 84.01 on Tuesday. Pacira Pharmaceuticals has a one year low of $26.72 and a one year high of $86.73. The stock’s 50-day moving average is $77.00 and its 200-day moving average is $67.81. The company’s market cap is $2.995 billion.

Pacira Pharmaceuticals (NASDAQ:PCRX) last issued its quarterly earnings data on Thursday, May 1st. The company reported ($0.19) EPS for the quarter, beating the Thomson Reuters consensus estimate of ($0.32) by $0.13. The company had revenue of $36.70 million for the quarter, compared to the consensus estimate of $35.40 million. The company’s quarterly revenue was up 216.4% on a year-over-year basis. On average, analysts predict that Pacira Pharmaceuticals will post $-0.57 earnings per share for the current fiscal year.

Pacira Pharmaceuticals, Inc is a United States-based pharmaceutical company. The Company develops non-opioid products for postsurgical pain control.

The Fly On The Wall

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.